|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300070671 |
|
最近更新日期: Date of Last Refreshed on: |
2023-04-19 17:57:28 |
|
注册时间: Date of Registration: |
2023-04-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
超声动态评估体位引流碎石系统对脑血流和颅内压的影响 |
|
Public title: |
The effect of postural drainage lithotripsy on cerebral blood flow and intracranial pressure was evaluated by ultrasonography |
|
注册题目简写: |
体位引流碎石系统的安全性研究 |
|
English Acronym: |
Safety study of body-position drainage lithotripsy system |
|
研究课题的正式科学名称: |
动态评估肾残留碎石体位引流处理过程中脑血流、颅内压以及血流动力学的影响 |
|
Scientific title: |
Dynamic assessment of cerebral blood flow, intracranial pressure, and hemodynamics during postural drainage treatment of renal residual lithotripsy |
|
研究课题代号(代码): Study subject ID: |
SJCX22_1880 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
2023-SR-086 |
|
申请注册联系人: |
戴亮亮 |
研究负责人: |
史红雷 |
|
Applicant: |
Liangliang Dai |
Study leader: |
HongLei Shi |
|
申请注册联系人电话: Applicant telephone: |
+86 13776466079 |
研究负责人电话:
Study leader's |
+86 13861287151 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1165145250@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
dashi7810@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省常州市天宁区永宁北路2号江苏大学附属武进医院 |
研究负责人通讯地址: |
江苏省常州市天宁区永宁北路2号江苏大学附属武进医院 |
|
Applicant address: |
Wujin Hospital Affiliated with Jiangsu University, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province, China |
Study leader's address: |
Wujin Hospital Affiliated to Jiangsu University, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
213017 |
研究负责人邮政编码: Study leader's postcode: |
213017 |
|
申请人所在单位: |
常州市武进人民医院 |
||
|
Applicant's institution: |
Changzhou Wujin People's Hospital |
||
|
研究负责人所在单位: |
常州市武进人民医院 |
||
|
Affiliation of the Leader: |
Changzhou Wujin People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-SR-086 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
常州市武进人民医院 |
||
|
Name of the ethic committee: |
Changzhou Wujin People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-02-28 00:00:00 | ||
|
伦理委员会联系人: |
张海燕 |
||
|
Contact Name of the ethic committee: |
Haiyan Zhang |
||
|
伦理委员会联系地址: |
江苏省常州市天宁区永宁北路2号常州市武进人民医院6号楼1楼伦理办公室 |
||
|
Contact Address of the ethic committee: |
Ethics Office, 1st Floor, Building 6, Wujin People's Hospital, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 519 85579190 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
常州市武进人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Changzhou Wujin People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省常州市天宁区永宁北路2号江苏大学附属武进医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Wujin Hospital Affiliated with Jiangsu University, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2022年江苏省研究生实践创新计划基金资助(SJCX22_1880);2022年度南京医科大学常州医学中心临床研究项目基金资助(CMCC202211) |
||||||||||||||||||||||
|
Source(s) of funding: |
2022 Jiangsu Province Postgraduate Practice Innovation Program Fund Grant (SJCX22_1880); 2022 Clinical Research Project Fund Grant (CMCC202211) from Changzhou Medical Center, Nanjing Medical Universit |
||||||||||||||||||||||
|
研究疾病: |
泌尿结石 |
||||||||||||||||||||||
|
Target disease: |
Urinary calculus |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
本研究团队开发的体位引流碎石系统(Postural drainage lithotripsy system,PLDS)可以准确清除微创术后肾脏中的残留碎石(Residual fragments,RFs)。PDLS包括结石清除路径规划软件和翻转床。翻转床通过达到软件计算出特定的空间角度,从而利用重力促进RFs的自发排泄。该床在x轴上旋转角度为-90°至+90°,在y轴旋转角度为-60°至+60°。对于真实患者,我们认为y轴旋转时左右翻转不会影响自身生命体征状况,然而x轴倒置时对于患者安全性还有待商榷。对于已知血管疾病,如颈动脉狭窄或有短暂性脑缺血发作史的患者,该体位可增加颅内压升高和颅内高压的风险,导致术后并发症。因此,本研究利用超声评价PDLS治疗残留碎石时对颅内压及脑血流的影响来探究其安全性是至关重要的。 |
||||||||||||||||||||||
|
Objectives of Study: |
The Postural drainage lithotripsy system (PLDS) developed by the research team can accurately remove Residual fragments (RFs) in the kidney after minimally invasive surgery. The PDLS include stone removal path planning software and a rollover bed. The flip bed uses gravity to promote spontaneous excretion of RFs by reaching a specific spatial Angle calculated by the software. The bed rotates from -90° to +90° on the X-axis and from -60° to +60° on the Y-axis. For real patients, we believe that the left and right rotation when the Y-axis rotates will not affect their own vital signs, while the safety of patients when the X-axis is inverted remains to be discussed. In patients with known vascular disease, such as carotid artery stenosis or a history of transient ischemic attacks, this position can increase the risk of increased intracranial pressure and intracranial hypertension leading to postoperative complications. Therefore, it is very important for this study to explore the safety of PDLS in the treatment of residual lithotripsy by using ultrasound to evaluate its effects on intracranial pressure and cerebral blood flow. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
随机选取年龄分布为 <40岁、40-60岁、>60岁健康受试者各5名。 |
||||||||||||||||||||||
|
Inclusion criteria |
Five healthy subjects aged <40 years, 40-60 years and >60 years were randomly selected. First each subject completed a survey on past medical history, age and gender and underwent a general health screening assessment. |
||||||||||||||||||||||
|
排除标准: |
如果受试者有以下任何病史:脊髓损伤、椎间盘突出、脑震荡、脑损伤、眼外伤、视力障碍、青光眼、呼吸系统疾病、静息血压高(收缩期> 160mmHg、舒张期> 90mmHg)、心电图异常(S—T抑制、>连续3次异位搏动)及未通过TCD获得MCAV则被排除在外。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Subjects were excluded if they had any of the following medical histories: spinal cord injury, herniated disc, concussion, brain injury, ocular trauma, visual impairment, glaucoma, respiratory disease, high resting blood pressure (> 160 mmHg systolic, > 90 mmHg diastolic), ECG abnormalities (S-T suppression, > 3 consecutive ectopic beats) and MCAV not obtained by TCD were excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-04-19 00:00:00至 To 2023-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-19 00:00:00 至 To 2023-05-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不涉及 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Not applicable |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
None |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |